Program
July 10
| Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|
| 18:00-18:10 | Welcome Address | |||
| 18:10-19:30 | Keynote | Alice T. Shaw Hiroyuki Mano |
Hiroyuki Mano (National Cancer Center Research Institute) |
Construction of Cancer Genomic Medicine Platform in Japan |
| Alice T. Shaw (Massachusetts General Hospital) |
Evolution of Resistance and Tumor Heterogeneity in ALK-Positive Lung Cancer | |||
| 19:50-21:50 | Welcome Party | |||
July 11
| Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|
| 8:30-10:00 | 1. Personalized treatment strategies in lung cancer | Alexander E. Drilon Koichi Goto |
Shinji Kohsaka (National Cancer Center Research Institute) |
Application of a High-throughput Functional Evaluation of Variants of Unknown Significance to Personalized Medicine |
| Alexander E. Drilon (Memorial Sloan Kettering Cancer Center) |
Advances in Targeted Therapy For Driver-Positive Subsets Of Non-Small Cell Lung Cancers | |||
| Koichi Goto (National Cancer Center Hospital East) |
Development of a Nationwide Genomic Screening Project (LC-SCRUM-Japan) for the Establishment of Precision Medicine in Lung Cancer | |||
| 10:00-10:20 | Break | |||
| 10:20-11:50 | 2. Latest advances in small cell lung cancer and mesothelioma | Charles M. Rudin Hiroyuki Aburatani |
Charles M. Rudin (Memorial Sloan Kettering Cancer Center) |
Latest Advances in Small Cell Lung Cancer |
| Hiroyuki Aburatani (The University of Tokyo) |
Comprehensive Molecular Analysis of Malignant Pleural Mesothelioma | |||
| Shoutaro Tsuji (Kanagawa Cancer Center) |
Development of Precise Diagnosis with a New Mesothelioma Marker, Sialylated HEG1 | |||
| 11:50-12:50 | Lunch and Poster View | |||
| 12:50-14:20 | Poster Presentation | |||
| 14:20-15:50 | 3. Targeting KRAS-mutant lung cancer | Ferdinandos Skoulidis Hiroki Nagase |
Ferdinandos Skoulidis (The University of Texas MD Anderson Cancer Center) |
Dissecting Immunotherapy Responses in Subgroups of KRAS-Mutant Lung Adenocarcinoma |
| Hiromichi Ebi (Aichi Cancer Center) |
Combination Therapies Targeting KRAS Mutant Lung Cancer | |||
| Hiroki Nagase (Chiba Cancer Center Research Institute) |
Targeting the RAS Gene Against Cancer | |||
| 15:50-16:10 | Break | |||
| 16:10-17:40 | 4. Overcoming resistance to targeted therapies in lung cancer | Christine M. Lovly Takashi Takahashi |
Takashi Takahashi (Nagoya University Graduate School of Medicine) |
ROR1: An Achilles Heel of Lung Cancer |
| Christine M. Lovly (Vanderbilt University Medical Center) |
Overcoming Resistance to Mutant-Selective EGFR Inhibition in EGFR-mutant Lung Cancer | |||
| Ryohei Katayama (Cancer Chemotherapy Center of JFCR) |
Drug Repurposing: Overcoming the Acquired Resistance with Other Target Inhibitors | |||
| 18:00-19:00 | Meet-the-Expert Evening (all participants) | |||
| 19:30-21:30 | Banquet | |||
July 12
| Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|
| 8:30-10:00 | 5. Novel immunotherapy strategies: Beyond PD-1/PD-L1 | Justin F. Gainor Hiroyoshi Nishikawa |
Hiroyoshi Nishikawa (National Cancer Center Research Institute) |
Complexed Immune Suppressive Mechanisms In Tumor Microenvironment |
| Justin F. Gainor (Massachusetts General Hospital) |
Emerging Immunotherapy Combinations in the Management of Non-Small Cell Lung Cancer | |||
| Koji Tamada (Yamaguchi University Graduate School of Medicine) |
Revolution of CAR-T Cell Technology to Develop Next-generation Cancer Immunotherapy | |||
| 10:00-10:20 | Break | |||
| 10:20-11:50 | 6. Primary and acquired mechanisms of resistance to immunotherapies | Roy S. Herbst Heiichiro Udono |
Kenji Chamoto (Kyoto University) |
The Role of Fatty Acid Oxidation of T Cells in the Synergistic Effect With PD-1 Blockade |
| Heiichiro Udono (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences) |
Anti-diabetes Drug, Metformin, Drives Metabolic Reprogramming of Tumor Microenvironment, Leading to Inhibition of Tumor Growth | |||
| Roy S. Herbst (Yale Cancer Center) |
Primary and Acquired Mechanisms of Resistance to Immunotherapies | |||
| 11:50-12:50 | Lunch | |||
| 12:50-14:20 | 7. Tumor heterogeneity and circulating tumor DNA | Maximilian Diehn Seiji Yano |
Seiji Yano (Cancer Research Institute of Kanazawa University) |
Inter-organ Heterogeneity on Mechanisms of Targeted Drug Resistance -Central Nervous System (CNS) vs extra CNS- |
| Maximilian Diehn (Stanford University) |
Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring | |||
| Tsukasa Kadota (National Cancer Center Research Institute) |
Circulating MicroRNAs as Biomarkers for Early Detection and Prediction of Immunotherapeutic Response in Lung Cancer Patients | |||
| 14:20-14:40 | Break | |||
| 14:40-16:10 | 8. Tumor microenvironment and implications for treatment | Miguel F. Sanmamed Kohei Miyazono |
Atsushi Enomoto (Nagoya University Graduate School of Medicine) |
Heterogeneity of Cancer-Associated Fibroblasts and its Significance in Tumor Progression and Response to Therapies |
| Miguel F. Sanmamed (Yale University) |
Modeling Patient-derived Lung Tumor Microenvironment To Develop Immunotherapies | |||
| Kohei Miyazono (The University of Tokyo) |
Regulation of the Development of Lung Cancer by TGF-β Signaling | |||
| 16:10-16:20 | Closing Remarks | |||